Literature DB >> 24254520

[The MEmbeR Multicenter Study on medical-occupational rehabilitation].

J D Rollnik1, M Sailer2, J Kiesel3, H Karbe4, J Harms5, C Busch6, R Eckhardt7, M Spranger8, D Rixecker9, R J Knickenberg10, R Weber11, H-J Hesselschwerdt12, K Scheidtmann13, M Köhler14, C Müller15, T Platz16, U Specht17, T Schmelter18, H Hoff-Emden19, D Urbach20, J Lecheler21.   

Abstract

INTRODUCTION: MEmbeR is a prospective multi-center study on medical-occupational rehabilitation in Germany.
METHODS: 196 neurological, psychiatric, orthopaedic, and internal medicine patients from 21 rehabilitation centres all across Germany have been enrolled and followed-up for 2 years after discharge. Primary outcome parameter was defined as return to work. Further, the SF-12 and a Mini-ICF-Rating have been used.
RESULTS: Mean age was 34.1 (9.9) years, length of stay 150.0 (223.5) days. Prior to occupational rehabilitation, 69.9% were unable to work, 2 years after discharge only 5.6%. Rate of participants seeking a job was reduced from 19.7% to 3.1%. In summary, 78.1% returned to work. Employed participants were younger (32.8 [9.7] vs. 38.5 [9.4] years, p=0.001) and less disabled (Degree of Disablement [GdB]: 20.0 [31.2] vs. 36.1 [33.7], p<0.05).
CONCLUSION: The multicenter cohort study MEmbeR provides further knowledge about the outcome of medical-occupational rehabilitation in Germany. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 24254520     DOI: 10.1055/s-0033-1347231

Source DB:  PubMed          Journal:  Rehabilitation (Stuttg)        ISSN: 0034-3536            Impact factor:   1.113


  2 in total

1.  [Telerehabilitation can not replace traditional neurological rehabilitation].

Authors:  J D Rollnik; M Pohl; T Mokrusch; C W Wallesch
Journal:  Nervenarzt       Date:  2017-10       Impact factor: 1.214

2.  The Early Functional Abilities (EFA) scale to assess neurological and neurosurgical early rehabilitation patients.

Authors:  Ariane Hankemeier; Jens D Rollnik
Journal:  BMC Neurol       Date:  2015-10-19       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.